There are 2137 resources available
551P - Phase I study of lurbinectedin in Japanese patients with pretreated advanced tumours: Final results
Presenter: Shunji Takahashi
Session: E-Poster Display
Resources:
Abstract
552P - Safety and efficacy of long-term exposure (LTE) to tislelizumab in Chinese patients with advanced solid tumours
Presenter: Lin Shen
Session: E-Poster Display
Resources:
Abstract
553P - Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J
Presenter: Roisin Connolly
Session: E-Poster Display
Resources:
Abstract
554P - Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: E-Poster Display
Resources:
Abstract
555P - Metronomic oral vinorelbine (MOV) combined with tremelimumab (T) + durvalumab (D) in advanced solid tumours (AST): Dose finding results
Presenter: Anthony Gonçalves
Session: E-Poster Display
Resources:
Abstract
556P - Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: Data from the phase Ib/II LIO-1 study (CO-3810-101; NCT04042116)
Presenter: Erika Hamilton
Session: E-Poster Display
Resources:
Abstract
557P - Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial
Presenter: Patrizia Froesch
Session: E-Poster Display
Resources:
Abstract
558P - A phase I study of rebastinib and carboplatin in patients with metastatic solid tumours
Presenter: Filip Janku
Session: E-Poster Display
Resources:
Abstract
559P - Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)
Presenter: Luis Paz-Ares
Session: E-Poster Display
Resources:
Abstract
560P - Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment
Presenter: Analia Azaro Pedrazzoli
Session: E-Poster Display
Resources:
Abstract